 The aim of this study is to determine whether alternating courses of cyclophosphamide, doxorubicin, vincristine, prednisonedexamethasone, cytarabine, cisplatin CHOPDHAP plus rituximab followed by total body irradiation TBIhigh dose cytarabine ARA-Cmelphalan-peripheral blood stem cell transplantation TAM-PBSCT can improve the time to treatment failure compared to CHOP plus rituximab followed by standard PBSCT dexamethasone, carmustine, cytarabine, etoposide, and melphalan Dexa-BEAMTBIhigh dose cyclophosphamide in patients with untreated mantle cell lymphoma. 